Development of targeted therapy and immunotherapy for treatment of small cell lung cancer

Japanese Journal of Clinical Oncology
Motonobu SaitoKoji Kono

Abstract

Targeted therapy against druggable genetic aberrations has shown a significantly positive response rate and longer survival in various cancers, including lung cancer. In lung adenocarcinoma (LADC), specific thyroxin kinase inhibitors against EGFR mutations and ALK fusions are used as a standard treatment regimen and show significant positive efficacy. On the other hand, targeted therapy against driver gene aberrations has not been adapted yet in small cell lung cancer (SCLC). This is because driver genes and druggable aberrations are rarely identified by next generation sequencing in SCLC. Recent advances in the understanding of molecular biology have revealed several candidate therapeutic targets. To date, poly [ADP-ribose] polymerase (PARP), enhancer of zeste homologue 2 (EZH2) or delta-like canonical Notch ligand 3 (DLL3) are considered to be druggable targets in SCLC. In addition, another candidate of personalized therapy for SCLC is immune blockade therapy of programmed death-1 (PD-1) and its ligand, PD-L1. PD-1/PD-L1 blockade therapy is not a standard therapy for SCLC, so many clinical trials have been performed to investigate its efficacy. Herein, we review gene aberrations exploring the utility of targeted therapy and d...Continue Reading

References

Dec 10, 2003·Clinical Lung Cancer·Yuichiro Ohe, Nagahiro Saijo
Sep 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ramaswamy GovindanJay Piccirillo
Apr 8, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Primo N LaraDavid R Gandara
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Mar 6, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·A Nigel BrooksPaul D Smith
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Sep 11, 2012·Nature·UNKNOWN Cancer Genome Atlas Research Network
Oct 5, 2012·Proceedings of the National Academy of Sciences of the United States of America·Martin L SosRoman K Thomas
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alice T Shaw, Jeffrey A Engelman
May 30, 2013·Genes, Chromosomes & Cancer·Reika IwakawaJun Yokota
Mar 22, 2014·Cancer Cell·Patricia A J Muller, Karen H Vousden
Aug 1, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Aug 15, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Shigeki UmemuraKoichi Goto
Sep 30, 2014·The New England Journal of Medicine·Alice T ShawA John Iafrate
Apr 10, 2015·Cancer Research·Motonobu SaitoTakashi Kohno
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Jun 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mehdi TouatJean-Charles Soria
Jul 15, 2015·Nature·Julie GeorgeRoman K Thomas
Jul 30, 2015·Genes & Development·Ekaterina A SemenovaAnton Berns
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Feb 6, 2016·Nature Medicine·Kimberly H Kim, Charles W M Roberts
Mar 31, 2016·Cancer Science·Motonobu SaitoTakashi Kohno
Jun 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott GettingerMatthew D Hellmann
Jul 28, 2016·Cold Spring Harbor Perspectives in Medicine·Ana I RoblesCurtis C Harris
Sep 14, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Julie GeorgeTakashi Kohno
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Mar 11, 2017·Surgery Today·Motonobu SaitoTakashi Kohno
Mar 18, 2017·Science·Christopher J Lord, Alan Ashworth
May 24, 2017·Nature Reviews. Clinical Oncology·Joshua K SabariCharles M Rudin

❮ Previous
Next ❯

Citations

Jun 20, 2019·Journal of Hematology & Oncology·Dwight H OwenKai He
Apr 14, 2020·Cell Biology International·Yuwen WangShi Xu
Mar 16, 2021·Molecular Therapy Oncolytics·Anna SchwendenweinBalazs Dome
Aug 10, 2021·Frontiers in Endocrinology·Elisa GiannettaAntongiulio Faggiano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.